STOCKS TELEGRAPH

Author: Maria Masood

  • Here’s What you Should Know About Inclining Premarket Stock of Aptorum Group Ltd. (APM)

    Aptorum Group Ltd. (APM) is a leading biotherapeutics company. It is engaged in the development and commercialization of treatments for oncology and infectious diseases. The company also focuses on its therapeutics platform for gastro and metabolic issues along with women’s health.

    The price of APM stock during the regular trading on January 24, 2022 was $1.62 with 9.46% incline. At last check in the premarket on January 25, 2022, the stock further rocketed by 42.5%.

    APM: Events and Happenings

    On January 20, 2022, APM reported about the grant of Orphan Drug Designation to SACT-1 by FDA. It is utilized in treating patients with Neuroblastoma. The company is also expecting to file IND application to commence phase 1/2 studies. On January 18, 2022, APM reported about the grant of preliminary patent status for the SACT-1 by the US Patent and Trademark Office.

    APM on January 10, 2022, reported that its subsidiary had commenced the clinical authentication of its rapid pathogen diagnostics liquid biopsy technology for diagnosing the pathogens. On January 10, 2022, APM reported about initiation of its cancer and autoimmune development portfolio. On January 10, 2022, APM reported about closure of clinical trials for ALS-4 and evaluating the relative bioavailability and food impact of SACT-1.

    APM on December 3, 2021, reported about the outcomes of 2021 annual general meeting of stockholders held on December 2. The stockholders re-elected all the current management of the company. Along with approving the re-appointment of company’s independent auditors, the stockholders also approved amendments to different articles.

    APM: Key Financials

    On September 15, 2021, APM reported its financial results for the six months ended June 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic and diluted net loss per share in H1 2021 was $17.1 million or $0.47 compared to $7.0 million or $0.21 for the same period in 2020.

    Assets

    Total current assets of the company in first half of 2021 were $21.9 million.

    Conclusion

    APM stock is 39% down the past half yearly period due to the economic restrictions imposed by the global pandemic. The current premarket surge in stock is the result of uncertain reasons as the company has not reported any recent news regarding its activities. The financial specialists are expecting more accomplishments from the company in the coming days.

  • Mustang Bio, Inc. (MBIO) Stock Showing Muted Response to This News

    Mustang Bio, Inc. (MBIO) is a leading biotherapeutics firm engaged in development of gene therapies to cure oncological disorders. One of the lead pipeline candidate therapy of the company is CAR-T used in treating solid tumors. Other candidates include MB-107 and MB-102 used for their therapeutic potential against X-linked severe combined immunodeficiency.

    The price of MBIO stock during the regular trading on January 24, 2022 was $1.30. At last check in the premarket on January 25, 2022, the stock showed no significant change.

    MBIO: Events and Happenings

    On January 24, 2022, MBIO reported about FDA issued hold on its IND application for Phase 2 trial of MB-207 as the Chemistry, Manufacturing and Controls were not clear.

    MBIO: CEO Comments

    Speaking at the occasion, MBIO’s CEO Manuel Litchman said that the company appreciated the support of FDA through the advancement of MB-107 and MB-207 as potential lead candidates. He further added that the company is looking forward to initiate its Phase 2 study of MB-107 under the company’s sponsored IND.

    On January 07, 2022, MBIO reported that the interim data of MB-106 was nominated for a poster presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings being held on February 2 – 6, 2022.

    On January 05, 2022, MBIO reported that the company’s Executives presented at three invertor conferences, held virtually.

    • 11thAnnual LifeSci Partners Corporate Access Event held on January 7.
    • C. Wainwright BioConnect Conference held on January 10.
    • Riley Securities’ Oncology Conference being held on January 28, 2022.

    On December 16, 2021, MBIO reported about its addition to NASDAQ Biotechnology Index with effect from December 20, 2021. On December 09, 2021, MBIO reported about hosting a webinar on MB-106 held on December 16, 2021.

    MBIO: Key Financials

    On November 12, 2021, MBIO reported its financial outcomes for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $17.0 million, or $0.19 versus $13.0 million, or $0.23, for the same quarter of 2020.

    Assets

    Total current assets of the company recorded in Q3 2021 were $121 million.

    Conclusion

    MBIO stock dipped 52% the past six months due to prevalence of pandemic globally. No change in the stock price in the current premarket is the result of hold placed by FDA on the company’s IND application for MB-207. The analysts are of the view that the company will recover on a faster pace from this situation with the help of its partners.

  • Brown & Brown, Inc. (BRO) Stock Rocketing Higher in Aftermarket, Here’s the Reason.

    Brown & Brown, Inc. (BRO) is a key insurance brokerage company engaged in delivery of solutions for risk management to customers. The company operates in four sectors including wholesale brokerage, retail services and national programs.

    The price of BRO stock during the regular trading on January 24, 2022 was $64.61 with a gain of 2.34%. At last check in the aftermarket, the stock further rocketed by 17.63%.

    BRO: Key Financials

    On January 24, 2022, BRO reported its financial results for the fourth quarter ended December 31, 2021. Some of the key updates are as follows.

    Revenue and Assets

    Total revenue in Q4 2021 was $738.5 million compared to same period of 2020 when it was $642.1 million. Total current assets in fourth quarter 2021 were $3330 million.

    Net Income per Share

    Basic and diluted net income per share in Q4 2021 was $101.7 million or $0.36 compared to Q4 2020 when it was $97.3 million or $0.34.

    BRO: Events and Happenings

    On January 20, 2022, BRO reported about the cash dividend of $0.1025 per share by the BoD’s payable to stockholders by February 16, 2022. BRO reported on January 03, 2022, that one of the company’s subsidiary had purchased all the assets of HARCO Insurance Services.

    On December 14, 2021, BRO reported that the company’s subsidiary had acquired all the assets of Rainmaker Advisory LLC. On December 13, 2021, BRO reported that one of the company’s subsidiary had acquired all the assets of Dealer Admin Services, Inc.

    BRO reported on December 13, 2021, that one of the company’s subsidiary had purchased all the assets of Corporate Insurance Advisors, L.L.C. on November 12, 2021, BRO reported that the company’s subsidiary had acquired all the assets of Heacock Insurance Group, Inc.

    Conclusion

    The company’s stock is playing well in the market despite the challenges faced by the company due to COVID-19 pandemic. The company’s stock is 18% up for the past six months period due to the sound strategies made by the management. The current aftermarket stock surge can be attributed to an increase of 15% or $96 million in quarterly revenue of the company.

  • Amarin Corp. PLC (AMRN) Stock Flying in the Aftermarket Here’s What Happened.

    Amarin Corp. PLC (AMRN) is a novel biotherapeutics company engaged in the development of treatment for cardiovascular diseases. The pipeline product candidate of the company is VASCEPA used as a diet adjunct to drop the level of triglyceride in hypertriglyceridemia patients.

    The price of AMRN stock during the regular trading on January 24, 2022 with a sip of 2.61% was $2.99. At last check in the aftermarket, the stock was significantly up by 6.35%.

    AMRN: Events and Happenings

    On January 24, 2022, AMRN reported about the recent SEC filing by the filer reporting the company’s common stock owned shares in a public company. On January 10, 2022, AMRN reported its preliminary 2021 full-year revenue outcomes. The company expected a 2021 full-year and Q4 revenue to be approximately $580 million and $140 million respectively.

    AMRN: CEO Comments

    Speaking at the occasion, AMRN CEO Karim Mikhail said that the company is developing a fixed dose combination of VASCEPA and a statin. He further added that the company’s vision to reduce heart diseases is the sole driver to the fast delivery of results.

    On January 04, 2022, AMRN reported that the company’s Executives presented at the Virtual 40th Annual J.P. Morgan Healthcare Conference held on January 11, 2022. On November 15, 2021 AMRN reported that the  VASCEPA data was presented at the American Heart Association Virtual Scientific Sessions 2021 held on November 13-15, 2021.

    On November 11, 2021, AMRN reported that the company’s Executives presented at the two investor conferences. They include Jefferies 2021 London Healthcare Conference held on November 16 and Virtual Piper Sandler 33rd Annual Healthcare Conference on November 22, 2021.

    AMRN: Key Financials

    On November 3, 2021, AMRN reported its financial results for the quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue and Assets

    Total revenue in Q3 2021 was $142 million versus $156 million in same period of 2020. Total current assets in Q3 2021 were $963 million.

    Net Loss per Share

    Basic and diluted net loss per share in Q3 2021 was $13.1 million or $0.03 versus $6.7 million or $0.02 in Q3 2020.

    Conclusion

    AMRN stock dipped 24% from the past six months period due to restrains put by the pandemic on the economic growth. The aftermarket stock increase is likely due to company’s recent SEC filing. The financial experts believe that, with this pace of strategic developments by the company, it will be able to attract the investors, despite its legal challenges .

  • CF Acquisition Corp. (CFV) Stock Dipping in Early Trading. Here’s What’s Happening.

    CF Acquisition Corp. (CFV) Stock Dipping in Early Trading. Here’s What’s Happening.

    CF Acquisition Corp. V (CFV) is a blank check company. The main focus of the company is impacting the business mergers, asset purchase, capital stock exchange, stock acquisition, and related functions.

    The price of the stock during the early trading on January 24, 2022, was last checked to be $9.81 with 23.15%.

    CFV: Events and Happenings

    On January 18, 2022, CF Acquisition Corp. (CFV)  and Satellogic reported about securing a supplementary $150 million private placement pledge from Liberty Strategic Capital (led by former Treasury Secretary Steven T. Mnuchin). Satellogic is a leading sub-meter resolution satellite imagery assembly.

    On December 30, 2021, CFV reported about convening and adjournment of its special meeting of shareholders held on the same day until January 24, 2022. Nettar Group Inc. and third-party investors were given extra time for the finalization of the terms of completion of PIPE financing for the advantage of the post-combination business.

    On December 28, 2021, Satellogic reported on the construction of a satellite manufacturing facility in the Netherlands. The new location will accelerate the assembly of satellites and accommodation of its equipment.

    Meeting Adjournment

    On December 8, 2021, CFV reported about adjourning of the special meeting of its shareholders until December 20, 2021. It allowed the company to re-discuss the extra financing for the post-combination business.

    On November 12, 2021, CFV and Satellogic co-reported that SEC had declared Satellogic’s form F-4 registration statement effective with regards to their proposed business merger.

    Conclusion

    CFV stock is 0.9% up in comparison to the past six months despite the restrictions put by the pandemic on economic growth. The current early trading drop is likely due to the company’s announcement regarding the multi-million investment in the company as predicted by the financial experts. The company is steadily moving towards more investment input from the stockholders.

  • Here’s the Reason of Growing Premarket Stock of HCW Biologics Inc. (HCWB).

    Here’s the Reason of Growing Premarket Stock of HCW Biologics Inc. (HCWB).

    HCW Biologics Inc. (HCWB) is an immunotherapy company engaged in the treatment of inflammation or chronic, low-grade inflammation and age-related diseases such as oncological disorders, diabetes, cardiovascular, neurodegenerative, and autoimmune diseases. The pipeline candidates of the company include HCW9218 for treating pancreatic cancer and HCW9302 for autoimmune disorders.

    The price of HCWB stock during the regular trading on January 21, 2022, was $2.02 with a steep 12.55% decrease. At last check in the premarket on January 24, 2022, the stock was significantly up by 4.95%.

    HCWB: Events and Happenings

    On January 24, 2022, HCWB reported about clearance by FDA for the Masonic Cancer Center for proceedings to assess HCW9218’s Phase 1 trial in solid tumor patients. The lead pipeline candidate of the company is an injectable, bifunctional fusion protein complex used to gear anti-tumor activity.

    On January 20, 2022, HCWB reported about its research paper publication in Molecular Therapy titled ‘Immunotherapeutic HCW9218 enhances the anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cells.’

    On January 19, 2022, the company reported that its Executives presented at the 24th Annual PepTalk Virtual Conference by Cambridge Healthtech Institute held on January 17-19, 2022. On January 06, 2022, HCWB reported that the company’s Executives presented at the H.C. Wainwright BioConnect Conference held on January 10 – 13, 2022.

    On December 13, 2021, HCWB reported that the company’s CEO Hing C. Wong was nominated by BioFlorida as the 2021 Entrepreneur of the Year.

    HCWB: Key Financials

    On November 12, 2021, HCWB reported its financial results for its third quarter ended September 30, 2021. Some of the key updates are as follows.

    Net Loss per Share

    Basic and diluted net loss in Q3 2021 was $4.1 million or $0.14 per share compared to $2.7 million or $0.63 per share in the same period of 2020.

    Assets

    Total current assets of the company in Q3 2021 were recorded to be $12.1 million.

    Conclusion

    HCWB stock dipped by 62% from the last half-year as a result of pandemic and slow economic growth. The current premarket rise in the company’s stock is due to the clearance received by the FDA. The analysts are suggesting that the company is outperforming in all the sectors despite the restrictions put by the pandemic.

  • Here’s What you Should Know about Surging Premarket Stock of NeuroBo Pharmaceuticals, Inc. (NRBO)

    Here’s What you Should Know about Surging Premarket Stock of NeuroBo Pharmaceuticals, Inc. (NRBO)

    NeuroBo Pharmaceuticals, Inc. (NRBO) is a leading innovative biotherapeutics company engaged in the development of treatments for neuropathic and neurodegenerative diseases. One of the lead pipeline candidates of the company is ANA001 is in Phase 2/3 clinical trial for the treatment of patients with COVID-19. NB-01 in Phase 2 trial for treating painful diabetic neuropathy patients. NB-02 for treating Alzheimer’s and Gemcabene for treating dyslipidemia and acute treatment for COVID-19.

    The price of NRBO stock during the regular trading on January 21, 2022, was $1.12 with a decline of 8.12%. At last check in the premarket on January 24, 2022, the stock was significantly up by 8.93%.

    NRBO: Key Financials

    On November 15, 2021, NRBO reported its financial results for the third fiscal quarter ended September 30, 2021. Some of the key updates are as follows

    Net Loss per Share

    Basic and diluted net loss for third-quarter 2021 was $3.5 million, or $0.16 per share compared to the same period of 2020 when it was $3.1 million, or $0.19 per share.

    Assets

    The total current assets of the company in Q3 2021 were $7.84 million.

    NRBO: Events and Happenings

    On November 4, 2021, NRBO reported about the appointment of Gil Price as President and CEO of the company. He had already served in eminent positions in leading global pharmaceutical industries. On October 13, 2021, NRBO reported that the safety data of patients in Phase 2/3 studies of ANA001 was reviewed by a Data Monitoring Committee. The results recommended the continuation of the clinical trials without any further adjustment.

    On October 5, 2021, NRBO reported about the closure of its direct registered offering of 4,307,693 shares of the common stock and warrants of the company acquired at a public price of $3.25 per share.  The gross proceeds from the acquisition were approximately $12.7 million used for corporate purposes.

    Conclusion

    NRBO stock decreased phenomenally 62% from the last six months due to the challenges faced by the industry because of the pandemic. The current premarket surge in the stock is the result of uncertain factors as there is no recent activity or news by the company. The analysts are predicting that the company’s potential drug pipeline is generating positive outcomes which will increase the investment options for the company in the coming days.

  • BT Brands, Inc. (BTBD) Stock Leaping Momentously in the Premarket. Here’s why.

    BT Brands, Inc. (BTBD) Stock Leaping Momentously in the Premarket. Here’s why.

    BT Brands, Inc. (BTBD) is engaged in the fast-food restaurant business known as Burger Time. The company operates various burger restaurants and one dairy queen franchise restaurant in different cities. The items offered by the company include chicken sandwiches, side dishes, ice-creams, and other desserts.

    The price of BTBD stock during the regular trading on January 21, 2022, was $2.46 with an 11.86% dip. At last check in the premarket on January 24, 2022, the stock skyrocketed by 118.80%.

    BTBD: Key Financials

    On November 17, 2021, BTBD announced its financial results for the third fiscal quarter ended October 3, 2021. Some of the key updates are as follows.

    Revenue

    Net sales in the third quarter of 2021 declined by $0.093 million to $2.28 million from $2.37 million in the same period of 2020.

    Net Income per Share

    Basic and diluted net income in the third quarter of 2021 was $0.58 million or $0.14 per share as compared to the same period in 2020 when it was $0.23 million or $0.06 per share.

    Assets

    Total current assets in the third quarter of 2021 were $2.24 million.

    BTBD: CEO Comments

    Speaking at the occasion, CEO of BTBD Gary Copperud said that the company had observed cost pressures in the commodities and labor market. He further added that the company managed the commodity cost hike via targeted menu cost regulations but the overall labor cost continued to be under pressure.

    On November 12, 2021, BTBD reported about the initial pricing of its public offering of 2,400,000 cohorts at a public price of $5.00 per cohort. Each cohort consisted of one common stock share and one warrant for the acquisition of one common stock share. The company received $12 million net proceeds from this acquisition. The common stock shares and warrants started trading on the Nasdaq Capital Market on November 12, 2021.

    Conclusion

    BTBD stock dipped 46% from the past six months period due to prevailing pandemic conditions which ceased the economy of the industry. The recent premarket boom in the stock market price is due to uncertain reasons as there is no current news available to point for the incline. The analysts are predicting more surge in the company’s stock which will have a positive impact on investor relations.

  • Here’s the Reason of Dolphin Entertainment, Inc. (DLPN) Stock Dipping in the Aftermarket.

    Here’s the Reason of Dolphin Entertainment, Inc. (DLPN) Stock Dipping in the Aftermarket.

    Dolphin Entertainment, Inc. (DLPN) is a global key entertainment advertising and production company. The company provides skilled marketing and commercialization services to the top brands, in the film, gaming, and hospitality businesses. The company’s NFTs sector designs distribute and promote NFTs in the TV, music, epicurean, and tech businesses.

    The price of DLPN stock during the regular trading on January 21, 2022, was $6.08 with a decrease of 0.33%. At last check in the aftermarket, the stock further significantly dipped by 9.54%.

    DLPN: Events and Happenings

    On January 20, 2022, DLPN reported the approaching readiness of NFT digital collectible platform that brings together comic heroes and athletes. The theme of the drop is Winter Sports Champion featuring current winter athletes’ legends participating in February Games. The collection will be released in collaboration with FTX.US.

    On December 8, 2021, DLPN reported about its entry into a strategic collaboration with Crafthouse Cocktails. The company managed the commercialization of the brand via its agencies network. Also, it facilitated the aptitude and commercial associations in both entertainment and culinary businesses.

    On November 22, 2021, DLPN reported about launching the content studio’s first generative NFT collection, Creature Chronicles: Exiled Aliens. The collection was minted in December and featured 10,000 exclusively-crafted avatars.

    DLPN: Key Financials

    On November 19, 2021, DLPN reported its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Revenue

    Total revenue in Q3 2021 recorded was $9.39 million versus $5.52 million in the same period in 2020.

    Net Income/Loss per Share

    Basic and diluted net income in Q3 2021 was $0.14 million or $0.02 per share versus a net loss of $0.13 million or $0.02 (basic) and $0.04 (diluted) in the same period of 2020.

    On October 12, 2021, DLPN reported about taking an ownership role in the Midnight Theatre by managing all commercialization aspects of the theater.

    Conclusion

    DLPN stock decelerated 27% in the last six months period due to the economic restrictions imposed by the spread of pandemics globally. The current aftermarket dip, as presumed by the financial experts, is the result of its collaboration for the NFT collection launch. The analysts are expecting some strict measures from the company in terms of attracting investment.

  • AMTD International Inc. (HKIB) Stock Inclining in the Early Trades Today. Here’s why.

    AMTD International Inc. (HKIB) is a leading super-connector of companies and investors from the global capital markets. The company is engaged in three sectors including asset management, investment banking, and strategic investment. The comprehensive financial portfolio of the company addresses the diverse financial needs of the clients.

    The price of HKIB stock during the early trading on January 21, 2022, was last checked to be $5.42 with a momentous rise of 15.32%.

    HKIB: Events and Happenings

    On January 20, 2022, HKIB reported about holding an extraordinary general meeting of its stockholders on March 1, 2022. The main agenda of the meeting is a name change from AMTD International Inc. to AMTD IDEA Group after approval by voting. The Company also reported changing the ticker symbol from AMTD with effect from January 31, 2022.

    On January 20, 2022, HKIB reported that its subsidiary had entered into a definitive contract for the acquisition of 100% of the equity interest in L’Officiel Inc. L’Officiel is a leading fashion media holding brand.

    HKIB: Chairman Comments

    Speaking at the occasion, HKIB Chairman Dr. Calvin Choi said that both the companies enabled connectivity and positioning as a major influencer in the global fashion. He further added that the purchase is the perfect catalyst for L’Officiel to lead the approval of Web technologies.

    HKIB: Key Financials

    On December 30, 2021, HKIB reported its financial results for the six months ended June 30, 2021. Some key points are as follows.

    Revenue

    Revenue for H1 2021 was HK$723.3 million compared to the same period of 2020 when it was HK$533.6 million. An increase of 35.6% was observed over the year.

    Assets

    Total current assets for H1 2021 were recorded to be HK$8632 million.

    On October 27, 2021, HKIB reported about the completion of partial voluntary early reacquisition of the SG Tranche Perpetual Securities worth $11,188,000, representing 22.38% of the total sum of the original issuance.

    Conclusion

    HKIB stock dipped by 1.99 % from the last six months period due to economic restrictions put by the pandemic. The current early market increase in stock price is the outcome of the company’s proposal of name and ticker change. The analysts believe that the company should design solid strategies with a futuristic approach to attract huge investment in the company.